Skip to main content
S&P 5007,704.81+1.80%DOW53,258.14+2.84%NASDAQ25,884.14+2.02%BTC$80,535.00+3.76%ETH$2,432.59+6.02%GOLD$4,078.30+3.50%OIL$88.78-7.61%
Smart Investors Daily
SID Premium
PR

NASDAQ · PRTA

Prothena Corporation plc Ordinary Shares

Healthcare · Biotechnology

$8.21

Up+$0.21 (+2.50%)

Updated Nov 4, 2026, 6:28 PM

SID Score

3.3/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
556.49M
P/E ratio
-1.98
Dividend yield
0.00%
52-week range
$7.73 – $11.80
Volume
289.88K
Avg. volume
643.8K

Price performance · PRTA

PRTA price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 3, 2026

PRTA closed at $8.21 after 21 trading sessions, up 2.37% for the selected period.

Last close
$8.21
Period change
+2.37%
Period low
$8.02
Period high
$9.10
Daily close
View OHLC price history
PRTA OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 3, 2026$8.30$8.49$8.15$8.21289.88K
Nov 2, 2026$8.45$8.49$8.105$8.29462.46K
Oct 30, 2026$8.79$8.90$8.345$8.47452.3K
Oct 29, 2026$9.10$9.26$8.75$8.88370.07K
Oct 28, 2026$8.64$9.22$8.605$9.10752K
Oct 27, 2026$8.40$8.85$8.35$8.81654.35K
Oct 26, 2026$8.34$8.49$8.21$8.40594.55K
Oct 23, 2026$8.18$8.268$7.93$8.20386.15K
Oct 22, 2026$8.01$8.285$7.96$8.25381.83K
Oct 21, 2026$8.47$8.54$8.01$8.03461.39K
Oct 20, 2026$8.55$8.645$8.45$8.50529.03K
Oct 19, 2026$8.39$8.57$8.31$8.48361.13K
Oct 16, 2026$8.58$8.62$8.24$8.35670.26K
Oct 15, 2026$8.54$8.65$8.44$8.50358.38K
Oct 14, 2026$8.28$8.56$8.19$8.37620.03K
Oct 13, 2026$8.45$8.55$8.20$8.36573.31K
Oct 12, 2026$8.81$8.81$8.395$8.43489.76K
Oct 9, 2026$8.57$9.305$8.50$8.84931.63K
Oct 8, 2026$8.43$8.81$8.36$8.61642.41K
Oct 7, 2026$7.93$8.63$7.88$8.48690.41K
Oct 6, 2026$8.28$8.28$7.80$8.02510.61K

Latest PRTA news

The latest Smart Investors Daily articles mentioning PRTA.

Stock researchCompany · Overview

PRTA research

Overview

Company profile and research snapshot.

Company profile

Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$26.00
Implied upside
—
Analysts
—
PRTA recent ratings
DateFirmRatingTarget
May 8, 2026CitizensMarket Outperform—
Feb 20, 2026RBC CapitalSector Perform—
Dec 1, 2025CitizensMarket Outperform—
Nov 7, 2025RBC CapitalSector Perform—
Nov 7, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 21, 2026

How Investors May Respond To Novo Nordisk (CPSE:NOVO B) Obesity Drug Competition

Novo Nordisk is pressing ahead with obesity and cardiometabolic drug development, including CagriSema regulatory submissions and a partnership with Prothena on Coramitug, while also running a DKK 15b share buyback that has added to its treasury share position since February 2026. Growing competition from Eli Lilly and Viking Therapeutics, together with fresh US scrutiny of GLP-1 linked supplement use, highlights both the strength of Novo Nordisk’s core obesity franchise and the regulatory...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By